Background and objectives. In contrast to the improvement in our understanding of the pathogenesis and presentation of autosomal recessive polycystic kidney disease (ARPKD), data regarding the issue of kidney and liver transplantation in patients with ARPKD remain particularly scarce. Here, we report the results and outcome of renal and/or liver transplantation in a series of patients with ARPKD.
Introduction
Autosomal recessive polycystic kidney disease (ARPKD) is an inherited disease with an estimated frequency of one in 20 000 live births [1] . It is characterized by the association of renal (enlarged hyperechogenic microcystic kidneys) and liver [congenital hepatic fibrosis (CHF), portal hypertension, Caroli's disease] manifestations. ARPKD is caused by mutations in the PKHD1 gene [2] that encodes fibrocystin/ polyductin (FPC). The latter colocalizes with polycstin-2 in the primary cilia and may contribute to the formation and maintenance of the focal adhesion complex in tubular cells [3, 4] .
ARPKD has long been considered to be exclusively a disorder of childhood, with an early diagnosis usually made during the neonatal or even the prenatal period. In the most severe forms, oligoamnios can lead to pulmonary hypoplasia and death during the neonatal period. Among the surviving children, 10-30% eventually reach end-stage renal disease (ESRD) before adulthood [1, 5] . Our understanding of ARPKD has been dramatically improved following the identification of the causative gene PKHD1 and the screening of a large cohort of children and adults for PKHD1 mutations in a leading work by Adeva et al. [6] . ARPKD has thus emerged as a highly heterogeneous disease with a wide spectrum of clinical manifestations including a renalpredominant phenotype with no or minor liver involvement or a hepatic-predominant phenotype with mild renal abnormalities frequently diagnosed in late childhood and more and more frequently in adulthood. Thus, ARPKD is no longer restricted to paediatric nephrology and nephrologists are increasingly involved in the management of adults with ARPKD.
ESRD, portal hypertension and angiocholitis in the setting of Caroli's disease remain the main complications of ARPKD and frequently lead to renal and/or liver transplantation. However, data regarding the outcome of patients with ARPKD after kidney and/or liver transplantations remain scarce.
Thus, we sought to assess the outcome of a cohort of children and adult patients with ARPKD who had received kidney and/or liver transplants.
Materials and methods
Patients with ARPKD who had undergone at least one renal transplantation, with or without liver transplantation, were included in the study. They were retrospectively identified through a query in the databases of five nephrology departments (three paediatric and two adults) in four teaching hospitals in France.
The diagnosis of ARPKD was made based on the following criteria:
1) a typical familial history suggestive of an autosomal recessive transmission including a negative screening of parents for renal and liver abnormalities;
2) typical kidney involvement on ultrasound scan with enlarged hyperechogenic microcystic kidneys with medullary and/or corticomedullary microcysts and/or precanicular tubular ectasia;
3) typical liver involvement defined as the presence of portal hypertension (hepatomegaly, splenomegaly, variceal bleeding, gastropathy) or Caroli's disease (dilatation of intra-or extra-hepatic bile ducts) or 4) a documented mutation in the PKHD1 gene.
Medical records of included patients were reviewed and relevant clinical and biological data regarding both the initial renal and hepatic disease and transplantation were collected: age at diagnosis, gender, renal and liver clinical manifestations, kidney and liver radiological findings, characteristics of renal and liver transplantation including infectious complications and cause of death. Glomerular filtration rate was estimated using the simplified Modification of Diet in Renal Disease formula in adults and Schwartz formula in children.
Results
We identified 14 ARPKD patients from 13 independent families (two cousins).
Patient characteristics
Clinical and radiological features of these 14 patients are summarized in Table 1 . In 72% of cases, ARPKD was diagnosed during the first year of life or during the prenatal period (n ¼ 10) (enlarged hyperechogenic kidneys, oligohydramnios). Diagnosis was made during infancy and childhood in two cases (14%) and in adulthood in two cases (14%). Six screened patients had a mutation detected in the PKHD1 gene. Median duration of follow-up before transplantation was 16 years (range: 3-28). Kidney size enlargement (79%), hypertension (64%) and proteinuria (50%) were the main renal features. Hepatomegaly (79%), portal hypertension manifestations (36-71%) and biliary ducts and liver infections (36%) were the most frequent hepatic manifestations. Imaging findings in the 14 patients included in the study are shown in Table 1 . Kidney enlargement was present in 79% of patients at diagnosis. However, renal atrophy (defined by a kidney volume lower than the one expected for the patient's age) was noted in 21% of cases at diagnosis and in 50% of cases during follow-up. Five patients (36%) presented with Caroli's disease associated to renal involvement typical of ARPKD in all cases.
Characteristics of renal and hepatic transplantations
Between 1980 and 2010, 18 kidney transplantations were performed in 14 ARPKD patients (Table 2 ). In all participating centres, ARPKD accounted for <0.5% of all kidney transplantations performed during the study period. Three patients had an orthotopic liver transplantation, performed 7-20 years after the kidney transplantation in two cases and simultaneously to kidney transplantation in one case. Six patients underwent kidney and/or liver transplantation in adulthood. In the 11 patients who received isolated renal transplantation, the median age at the time of the first renal transplantation was 13.5 years (3-25) and the median time between diagnosis and transplantation was 13 years (3-25). In the three patients who underwent kidney and liver transplantation, the median age at the time of the first renal or liver transplantation was 25.6 years (23-26) and 34.6 years (23-46), respectively.
The main indications for liver transplantation in all three patients were recurrent and/or severe cholangitis and/or the risk of malignant cholangiocarcinoma in the setting of Caroli's disease (Figure 1 ).
During the relatively long period during which the patients underwent renal and liver transplantation, various immunosuppressive regimens were used. All patients received an induction therapy with basiliximab (Simulect; Novartis) (58%) or anti-thymocyte globulin (Thymoglobulin; Genzyme) (42%). Bi-or tritherapy consisting of cyclosporine (50%) or tacrolimus (43%), combined with mycophenolate mofetil (58%) or azathioprine (43%) with or without steroids were used as a maintenance treatment.
The median duration of follow-up after transplantation was 7.8 years (1-25). Nine (64%) patients were followed in adulthood and the median duration of follow-up in adulthood was 13.1 years (2-28). Three patients were lost to follow-up.
Renal and liver transplantation-related complications
Fifteen episodes of infectious complications occurred in 10 patients and included viral infections (50%), bacterial urinary infections (21%) and liver infections (21%) ( Table 2) . Liver infections consisted of cholangitis (n ¼ 1), hepatic abscess (n ¼ 1) and septicaemia (n ¼ 1) complicating the course of Caroli's disease in all patients. Among the five patients with Caroli's disease, three experienced recurrent (three to five) episodes of angiocholitis after renal transplantation. One renal transplant patient with asymptomatic Caroli's disease underwent pre-emptive liver transplantation and did not present with hepatic infectious complications during follow-up.
At last follow-up [median range after transplantation: 7.8 years (1-25)], five patients had lost at least one kidney graft (33%) and one patient (25%) had lost one liver graft. Two patients and one patient underwent two and three successive renal transplantations, respectively. Actuarial survival of the first renal graft is shown in Figure 2 . First renal graft survival was 92, 78 and 14% at 1, 5 and 10 years after renal transplantation, respectively. For the second renal graft (n ¼ 3), actuarial graft survival was 100% at 1, 5 and 10 years and at 50% at 15 years after renal transplantation. One-third renal graft (n ¼ 1) was lost at 1 year after renal transplantation.
Renal grafts were lost due to chronic humoral rejection (n ¼ 4), early renal graft thrombosis (n ¼ 1) and acute rejection due to discontinuation of immunosuppressive treatments (n ¼ 1).
For the first hepatic graft (n ¼ 3), actuarial survival was 50 and 0% at 1 year and 3 years after transplantation, respectively.
Three patients died (Figure 2 ), two renal transplants and one renal and hepatic transplant. All deaths were due to hepatic complications in patients who had undergone renal transplantation: One male renal transplant patient with a neonatal form of ARPKD died at the age of 4 years (1 year after renal transplantation) in the setting of septic shock due to acute cholangitis complicating Caroli's disease. One female patient with severe liver involvement (CHF, portal hypertension, Caroli's disease with intrahepatic biliary lithiasis) died at the age of 21 years (7 years after renal transplantation) in the setting of septic shock due to acute chloangitis complicating Caroli's disease. One male patient who had previously lost two renal grafts died at the age of 46 years, 7 days after a combined kidney and liver transplantation (Caroli's disease). Death was due to multiorgan failure in the setting of severe sepsis due to cholangitis, which was most probably already present at the time of transplantation.
Discussion
Even though our understanding of the pathogenesis and presentation of ARPKD has been significantly improved during the last decade, data regarding the issue of kidney and liver transplantation in patients with ARPKD remain particularly scarce. One single series of patients with ARPKD undergoing renal transplantation has been previously reported [7] . It included 14 patients, mainly children (mean age 8.3 years) who had undergone renal or combined renal and hepatic transplantation (one case) over a long period of time dating back to 1972. Only three patients (21%) had been followed in adulthood.
The present study included relatively older patients (median age 13.5 years) of whom 64% had been followed in adulthood and six patients (43%) who underwent kidney and/or liver transplantation in adulthood. Interestingly, in two patients with severe liver involvement, the diagnosis of ARPKD had been made in adulthood after kidney transplantation. The present report underlines that ARPKD is definitely not restricted to paediatric nephrology and is further evidence that ARPKD is a heterogeneous disease with a wide spectrum of presentations.
Due to the improved management of perinatal ARPKD forms and the increased rate of successful long-term kidney and liver transplantations, adult nephrologists will be more and more frequently in charge of ARPKD patients who underwent kidney transplantation in childhood and who have reached adulthood. Moreover, patients with a history of liver transplantation in childhood are at high risk of developing in adulthood severe chronic renal disease requiring renal transplantation [8] . Finally, some patients with ARPKD may not reach ESRD until adulthood [9] and ARPKD may also be diagnosed in adulthood [6] , as exemplified by two cases in our study. Our data clearly show that the major issue in the management of patients with ARPKD undergoing renal transplantation is liver involvement and most particularly Caroli's disease. Caroli's disease belongs to the heterogeneous group of cystic hepatic and biliary disorders [10] , which include hepatic cysts non-communicating with biliary ducts (simple biliary cysts, autosomal dominant polycystic hepato-renal disease [11] , cystadenoma/ cystadenocarcinoma, infectious cysts) and intra-and extra-hepatic bile duct dilatation (Caroli's disease, CHF, hamartomas). Caroli's disease arises from a ductal plate malformation [12] (persistence of embryonic primitive configuration of the intrahepatic bile ducts) and is characterized by segmentary intrahepatic cystic bile duct dilatation. It can affect all or part of the liver, may be associated to CHF and frequently occurs in the absence of ARPKD. Caroli's disease may remain asymptomatic or lead to severe complications: cholangitis, hepatic abscess, septicaemia, intrahepatic biliary stones, acute pancreatitis, primitive biliary cirrhosis, cholangiocarcinoma [13] (5-10%) and amyloidosis in severe protracted biliary infections [14] .
In the present report, the relatively high mortality rate (21%) was directly related to Caroli's disease complications, most notably severe and recurrent angiocholitis. Moreover, Caroli's disease was the main indication for liver transplantation in ARPKD kidney transplant recipients. This is probably due to the natural history of Caroli's disease with progressive worsening over time and to the impact of immunosuppression following kidney transplantation on the incidence of biliary infections. In contrast to the previous report by Khan et al. [7] , the incidence of CHF and portal hypertension complications after transplantation was relatively low (7%) in our patients. Thus, our data suggest that ARPKD patients evaluated for renal transplantation should be carefully screened for severe Caroli's disease (extensive biliary ducts dilatations, history of recurrent cholangitis). In the presence of severe Caroli's disease, a combined liver and kidney transplantation should be discussed. Orthotopic liver transplantation is a relatively recent and rarely used (<0.2% of all liver transplantations in the USA [15] ) therapeutic option for patients with severe Caroli's disease [16] . The main indication for liver transplantation in these patients remains recurrent cholangitis. Two recent reports have assessed the outcome of liver transplantation in patients with severe Caroli's disease [15, 17] . Overall, liver transplantation improves patient survival (65% at 5 years), which is similar to the survival of patients undergoing the same procedure for other chronic liver diseases. Liver graft outcome is also excellent with a graft survival of 62-72% at 5 years. However, post- Fig. 1 . A 21-year-old male patient was diagnosed with chronic renal failure, renal colics and 'polycystic kidneys'. At the age of 28 years, he underwent a familial pre-emptive renal transplantation. Seven years later, he presented with recurrent severe angiocholitis requiring protracted courses of antibiotics. A non-enhanced abdominal computerized tomography scan showed massive dilatation of intrahepatic bile ducts (*). Kidneys were atrophic with the presence of several cysts (#). The diagnosis of ARPKD with Caroli's disease was made. The patient subsequently underwent an uneventful liver transplantation. At last follow-up, his serum creatinine was 117 lmol/L. transplantation mortality remains high and is mainly due to septic complications, most particularly in patients with cholangitis before or at the time of liver transplantation [15] . Thus, pre-emptive liver transplantation in ARPKD with ESRD and severe Caroli's disease (performed before the onset of infectious biliary complications) may help avoid recurrent biliary infections and may improve the survival of these patients.
In all, ARPKD is part of adulthood nephrology care whether in the setting of chronic kidney disease and/or renal transplantation. The main issue in the management of ARPKD undergoing renal transplantation is Caroli's disease. Even though the limited number of patients included in our study precludes any definite recommendation, pre-emptive liver transplantation may be a therapeutic option in ARPKD patients with severe Caroli's disease evaluated for renal transplantation.
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